BCL9L
B-cell CLL/lymphoma 9 like is a protein that in humans is encoded by the BCL9L gene. [1]
References
- ↑ “Entrez Gene: B-cell CLL/lymphoma 9 like”. Retrieved 2017-10-31.
Further reading
- Sampietro J, Dahlberg CL, Cho US, Hinds TR, Kimelman D, Xu W (2006). “Crystal structure of a beta-catenin/BCL9/Tcf4 complex”. Mol. Cell. 24 (2): 293–300. doi:10.1016/j.molcel.2006.09.001. PMID 17052462.
- Miller TC, Rutherford TJ, Johnson CM, Fiedler M, Bienz M (2010). “Allosteric remodelling of the histone H3 binding pocket in the Pygo2 PHD finger triggered by its binding to the B9L/BCL9 co-factor”. J. Mol. Biol. 401 (5): 969–84. doi:10.1016/j.jmb.2010.07.007. PMC 2927781. PMID 20637214.
- Brembeck FH, Wiese M, Zatula N, Grigoryan T, Dai Y, Fritzmann J, Birchmeier W (2011). “BCL9-2 promotes early stages of intestinal tumor progression”. Gastroenterology. 141 (4): 1359–70, 1370.e1–3. doi:10.1053/j.gastro.2011.06.039. PMID 21703997.
- Matsuura K, Jigami T, Taniue K, Morishita Y, Adachi S, Senda T, Nonaka A, Aburatani H, Nakamura T, Akiyama T (2011). “Identification of a link between Wnt/β-catenin signalling and the cell fusion pathway”. Nat Commun. 2: 548. doi:10.1038/ncomms1551. PMID 22109522.
- Zatula N, Wiese M, Bunzendahl J, Birchmeier W, Perske C, Bleckmann A, Brembeck FH (2014). “The BCL9-2 proto-oncogene governs estrogen receptor alpha expression in breast tumorigenesis”. Oncotarget. 5 (16): 6770–87. doi:10.18632/oncotarget.2252. PMC 4196162. PMID 25149534.
- El-Hage P, Petitalot A, Monsoro-Burq AH, Maczkowiak F, Driouch K, Formstecher E, Camonis J, Sabbah M, Bièche I, Lidereau R, Lallemand F (2015). “The Tumor-Suppressor WWOX and HDAC3 Inhibit the Transcriptional Activity of the β-Catenin Coactivator BCL9-2 in Breast Cancer Cells”. Mol. Cancer Res. 13 (5): 902–12. doi:10.1158/1541-7786.MCR-14-0180. PMID 25678599.
© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH